- Home
- STGW vs TNGX Comparison
STGW vs TNGX Comparison
Compare STGW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STGW | TNGX |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STGW | TNGX |
|---|---|---|
| Price | $5.28 | $16.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $8.25 | ★ $17.50 |
| AVG Volume (30 Days) | 1.4M | ★ 3.5M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,841,216,000.00 | $62,384,000.00 |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | $11.60 | $13.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.43 | ★ 48.29 |
| 52 Week Low | $4.03 | $1.04 |
| 52 Week High | $7.17 | $17.63 |
Technical Indicators
Market Signals| Indicator | STGW | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 71.50 |
| Support Level | $5.22 | $10.90 |
| Resistance Level | $5.66 | N/A |
| Average True Range (ATR) | 0.28 | 1.16 |
| MACD | 0.09 | 0.45 |
| Stochastic Oscillator | 93.02 | 82.50 |
Price Performance
Historical ComparisonAbout STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.